Drug intelligence / Profile preview

ABBV-141

Development stage: Phase 1
Lead developer: AbbVie
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

ABBV-141 is an investigational antifibrotic monoclonal antibody developed by AbbVie. It acts as a lysophosphatidic acid receptor 1 (LPAR1) antagonist, targeting the LPAR1 pathway implicated in the pathogenesis of fibrotic diseases. By inhibiting LPAR1, ABBV-141 aims to reduce inflammation and fibrosis, particularly in lung tissue. The drug is administered via intravenous (IV) or subcutaneous (SC) routes and is currently being evaluated in Phase I clinical trials for idiopathic pulmonary fibrosis (IPF).

Other names: ABBV 141ABBV141ABBV-141

Targets

LPAR1 (Lysophosphatidic acid receptor 1)

Beyond the preview

Go deeper on ABBV-141.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABBV-141.

Explore the full profile